In this episode titled: CRISPR/Cas: exploring its impact on gene editing, we explore the latest technological advancements in the field and more.This conversation features Dr Pietro De Angeli, Scientist at Tubingen University Hospital, and Dr Maarten Guerts, Postdoctoral Fellow at the Princess Maxima Center for Pediatric Oncology.Key learning points: What comparative safety profiles exist between utilising plasmid DNA, mRNA, and ribonucleoproteins (RNPs) as delivery systems for CRISPR/Cas components in gene editing therapies?In what ways might the use of different ex-vivo applications affect the scalability and feasibility of large-scale gene editing treatments?How might the convergence of CRISPR/Cas technology with Artificial Intelligence/Machine Learning improve precision medicine?